TABLE 2.

Clinical trials for hepatoblastoma.

NCT number	Drug	Condition	Conclusion	Ref
NCT00077389	Cisplatin	High-risk Hepatoblastoma	Feasible and effective	Kristensen et al. (2022)
NCT00980460	Cisplatin, fluorouracil, vincristine	Hepatoblastoma with surgical resection	Minimal post-operative chemotherapy ensures control of patient’s condition	Sunil et al. (2018)
NCT00003912	Cisplatin versus cisplatin plus doxorubicin	Standard-risk Hepatoblastoma	Similar rates of complete resection and survival	Filin et al. (2020)
NCT00428272	Lexatumumab	Hepatoblastoma	Showed a dramatic biomarker response	Moosburner et al. (2021)
NCT00929903	Pazopanib	Hepatoblastoma	Achieved a partial response	Hishiki, (2013)
NCT00652132	Sodium Thiosulfate, Cisplatin	Hepatoblastoma	Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss	Vogl et al. (2006)
NCT00716976	Sodium Thiosulfate	Hepatoblastoma	Protects against cisplatin-induced hearing loss	Wang et al. (2014)
NCT01331135	Sirolimus, metronomic therapy (CHOAnome)	Hepatoblastoma	Well tolerated	Li et al. (2017)